IL15 and acute myeloid leukemia: A single-center, dose-escalation study designed to determine the maximum tolerated, minimum efficacious dose (MTD/MED) of IL-15 (Intravenous Recombinant Human IL-15) and incidence of donor natural killer (NK) cell expansion by day +14 when given after haploidentical donor NK cells in patients with relapsed or refractory acute myelogenous leukemia (AML).